Información del artículo
El Texto completo está disponible en PDF
Bibliogrífia
[1.]
A.B. Hawthorne, C.J. Hawkey.
Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.
Drugs, 38 (1989), pp. 267-288
[2.]
D.C. Pearson, G.R. May, G.H. Fick, L.R. Sutherland.
Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis.
Ann Intern Med, 122 (1995), pp. 132-142
[3.]
M.A. Peppercorn.
6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come.
Am J Gastroenterol, 91 (1996), pp. 1689-1690
[4.]
J. Rhodes, D. Bainton, P.L. Beck, H. Campbell.
Controlled trial of azathioprine in Crohn’s disease.
Lancet, 2 (1971), pp. 1273-1276
[5.]
J.M. Willoughby, J. Beckett, P.J. Kumar, A.M. Dawson.
Controlled trial of azathioprine in Crohn’s disease.
Lancet, 2 (1971), pp. 944-947
[6.]
M. Klein, H.J. Binder, M. Mitchell, R. Aaronson, H. Spiro.
Treatment of Crohn’s disease with azathioprine: a controlled evaluation.
Gastroenterology, 66 (1974), pp. 916-922
[7.]
R.W. Summers, D.M. Switz, J.T. Sessions, J.M. Becketel, W.R. Best, F. Kern, et al.
National Cooperative Crohn’s disease study: results of drug treatment.
Gastroenterology, 77 (1979), pp. 847-869
[8.]
D.H. Present, B.I. Korelitz, N. Wisch, J.L. Glass, D.B. Sachar, B.S. Pasternack.
Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, radomized, double-blind study.
N Engl J Med, 302 (1980), pp. 981-987
[9.]
K. Ewe, A.G. Press, C.C. Singe, M. Stufler, B. Ueberschaer, G. Hommel, et al.
Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease.
Gastroenterology, 105 (1993), pp. 367-372
[10.]
S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig, R. Goodman.
A controlled double blind study of azathioprine in the management of Crohn’s disease.
Gut, 37 (1995), pp. 674-678
[11.]
J.L. Rosenberg, B. Levin, A.J. Wall, J.B. Kirsner.
A controlled trial of azathioprine in Crohn’s disease.
Dig Dis Sci, 20 (1975), pp. 721-726
[12.]
D.P. O’Donoghue, A.M. Dawson, J. Powell-Tuck, R.L. Bown, J.E. Lennard-Jones.
Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease.
Lancet, 2 (1978), pp. 955-957
[13.]
D.C. Pearson, G.R. May, G.H. Fick, L.R. Sutherland.
Azathioprine for maintaining remission in Crohn’s disease.
Cochrane Database Syst Rev, 2 (2000), pp. CD000067
[14.]
J. Markowitz, K. Grancher, N. Kohn, M. Lesser, F. Daum.
The Pediatric 6-MP Collaborative Group. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease.
Gastroenterology, 119 (2000), pp. 895-902
[15.]
Y. Bouhnik, M. Lémann, J.Y. Mary, G. Scemama, R. Taï, C. Matuchansky, et al.
Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine.
Lancet, 347 (1996), pp. 215-219
[16.]
P.S. Kim, J. Zlatanic, B.I. Korelitz, G.M. Gleim.
Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease.
Am J Gastroenterol, 94 (1999), pp. 3254-3257
[17.]
R. Modigliani.
Immunosuppressors for inflammatory bowel disease: how long is long enough?.
Inflammat Bowel Dis, 6 (2000), pp. 251-257
[18.]
B.I. Korelitz, D.J. Adler, R.A. Mendelsohn, A.L. Sacknoff.
Longterm experience with 6-mercaptopurine in the treatment of Crohn’s disease.
Am J Gastroenterol, 88 (1993), pp. 1198-1205
[19.]
J.L. Rosenberg, A.J. Wall, B. Levin, H.J. Binder, J.B. Kirsner.
A controlled trial of azathioprine in the management of chronic ulcerative colitis.
Gastroenterology, 69 (1975), pp. 96-99
[20.]
A.P. Kirk, J.E. Lennard-Jones.
Controlled trial of azathioprine in chronic ulcerative colitis.
BMJ, 284 (1982), pp. 1291-1292
[21.]
A.J. Lobo, P.N. Foster, D.A. Burke, D. Johnston.
Axon ATR. The role of azathioprine in the management of ulcerative colitis.
Dis Colon Rectum, 33 (1990), pp. 374-377
[22.]
J. George, D.H. Present, R. Pou, C. Bodian, P.H. Rubin.
The longterm outcome of ulcerative colitis treated with 6-mercaptopurine.
Am J Gastroenterol, 91 (1996), pp. 1711-1714
[23.]
S. Ardizzone, P. Molteni, V. Imbesi, S. Bollani, P.G. Bianchi, F. Molteni.
Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis.
J Clin Gastroenterol, 25 (1997), pp. 330-333
[24.]
E. Domènech, X. Aldeguer, E. Cabré, R. Vega, M. Esteve, F. Fernández Bañares, et al.
Azathioprine in inflammatory bowel disease: an 8-year study and assessment of response predictors [abstract].
Gastroenterology, 114 (1998), pp. A967
[25.]
D.P. Jewell, S.C. Truelove.
Azathioprine in ulcerative colitis: final report on controled therapeutic trial.
BMJ, 4 (1974), pp. 627-630
[26.]
A.B. Hawthorne, R.F. Logan, C.J. Hawkey, P.N. Foster, A.T. Axon, E.T. Swarbrick, et al.
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.
BMJ, 305 (1992), pp. 20-22
[27.]
S. Lichtiger, D.H. Present, A. Kornbluth, I. Gelernt, J. Bauer, G. Galler, et al.
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
N Engl J Med, 330 (1994), pp. 1841-1845
[28.]
A. Kornbluth, D.H. Present, S. Lichtiger, S. Hanauer.
Cyclosporin for severe ulcerative colitis: a user’s guide.
Am J Gastroenterol, 92 (1997), pp. 1424-1428
[29.]
W.J. Sandborn.
A critical review of cyclosporine therapy in inflammatory bowel disease.
Inflammat Bowel Dis, 1 (1995), pp. 48-63
[30.]
A. Kornbluth, S. Lichtiger, D.H. Present, S.B. Hanauer.
Long-term results of oral cyclosporin in patients with severe ulcerative colitis [abstract].
Gastroenterology, 106 (1994), pp. A714
[31.]
W.R. Treem, J. Cohen, P.M. Davis, C.J. Justinich, J.S. Hyams.
Cyclosporine for the treatment of fulminant ulcerative colitis in children: immediate response, long-term results, and impact on surgery.
Dis Colon Rectum, 38 (1995), pp. 474-479
[32.]
F. Fernández Bañares, X. Bertrán, M. Esteve Comas, E. Cabré, M. Menacho, P. Humbert, et al.
Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis.
Am J Gastroenterol, 91 (1996), pp. 2498-2499
[33.]
D.H. Present.
How to do without steroids in inflammatory bowel disease.
Inflammat Bowel Dis, 6 (2000), pp. 48-57
[34.]
M. Kusunoki, G. Moeslein, Y. Shoji, S. Fujita, H. Yanagi, Y. Sakanoue, et al.
Steroid complications in patients with ulcerative colitis.
Dis Colon Rectum, 35 (1992), pp. 1003-1009
[35.]
G.A. Akerkar, M.A. Peppercorn, M.B. Hamel, R.A. Parker.
Corticosteroid-associated complications in elderly Crohn’s disease patients.
Am J Gastroenterol, 92 (1997), pp. 461-464
[36.]
J. Jahnsen, J.A. Falch, E. Aadland, P. Mowinckel.
Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study.
Gut, 40 (1997), pp. 313-319
[37.]
S. Ardizzone, S. Bollani, P. Bettica, M. Bevilacqua, P. Molteni, G. Bianchi Porro.
Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis.
J Intern Med, 247 (2000), pp. 63-70
[38.]
J.A. Silvennoinen, T.J. Karttunen, S.E. Niemelae, J.J. Manelius, J.K. Lehtola.
A controlled study of bone mineral density in patients with inflammatory bowel disease.
Gut, 37 (1995), pp. 71-76
[39.]
E.J. Semeao, A.F. Jawad, N.O. Stouffer, B.S. Zemel, D.A. Piccoli, V.A. Stallings.
Risk factors for low bone mineral density in children and young adults with Crohn’s disease.
J Pediatr, 135 (1999), pp. 593-600
[40.]
E.G. Seidman.
6-Mercaptopurine in maintaining remission in Crohn’s disease: an old friend becomes a new hero.
Gastroenterology, 119 (2000), pp. 1158-1160
[41.]
G.R. D’Haens, P. Rutgeerts.
Postoperative recurrence of Crohn’s disease: pathophysiology and prevention.
Inflammat Bowel Dis, 5 (1999), pp. 295-303
[42.]
P. Rutgeerts, K. Geboes, G. Vantrappen, J. Beyls, R.P. Kerremans, M. Hiele.
Predictability of the postoperative course of Crohn’s disease.
Gastroenterology, 99 (1990), pp. 956-963
[43.]
C. Cammà, M. Giunta, M. Rosselli, M. Cottone.
Mesalamine in the maintenance treatment of Crohn’s disease: A meta-analysis adjusted for confounding variables.
Gastroenterology, 113 (1997), pp. 1465-1473
[44.]
H. Lochs, M. Mayer, W.E. Fleig, P.B. Mortensen, P. Bauer, D. Gienser, et al.
Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Crohn’s Disease Study V.I.
Gastroenterology, 118 (2000), pp. 264-273
[45.]
K. Ewe, T. Bottger, H.J. Buhr, K.W. Ecker, H.F. Otto, B. Ueberschaer, et al.
Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicenter randomized placebo-controlled trial.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 277-282
[46.]
G. Hellers, A. Cortot, D. Jewell, C.E. Leijonmarck, R. Löfberg, H. Malchow, et al.
Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease.
Gastroenterology, 116 (1999), pp. 294-300
[47.]
P. Rutgeerts, M. Peeters, M. Hiele, R.P. Kerremans, F.M. Penninckx, R. Aerts, et al.
A placebo controlled trial of metronidazole for recurrence prevention of Crohn’s disease after resection of the terminal ileum.
Gastroenterology, 108 (1995), pp. 1617-1621
[48.]
G.R. D’Haens, K. Geboes, E. Ponette, F.M. Penninckx, P. Rutgeerts.
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease.
Gastroenterology, 112 (1997), pp. 1475-1481
[49.]
H.A. Kader, S.C. Raynor, R. Young, S.S. Kaufman, J. Vanderhoof, E.I. Ruby, et al.
Introduction of 6-mercaptopurine in Crohn’s disease patients during the perioperative period: a preliminary evaluation of recurrence of disease.
J Ped Gastroenterol Nutr, 25 (1997), pp. 93-97
[50.]
B.I. Korelitz, S.B. Hanauer, P. Rutgeerts, D.H. Present, M.A. Peppercorn.
Postoperative prophylaxis with 6-MP, 5-ASA or placebo in Crohn’s disease: a two-year multicenter trial [abstract].
Gastroenterology, 114 (1998), pp. A1011
[51.]
P. Nos, J. Hinojosa, V. Aguilera, J.R. Molés, M. Pastor, J. Ponce, et al.
Azatioprina y 5-ASA en la prevención de la recurrencia posquirúrgica de la enfermedad de Crohn.
Gastroenterol Hepatol, 23 (2000), pp. 374-378
[52.]
I. Bernal, L. Scala, E. Domènech, M. Esteve, M. Piñol, E. García-Planella, et al.
Azatioprina (AZA) y mesalamina (5-ASA) como prevención de la recurrencia posquirúrgica en la enfermedad de Crohn (EC) [abstract].
Gastroenterol Hepatol, 24 (2001), pp. 95
[53.]
D.H. Present, P. Rutgeerts, S. Targan, S.B. Hanauer, L. Mayer, R.A. Van Hogezand, et al.
Infliximab for the treatment of fistulas in patients with Crohn’s disease.
N Engl J Med, 340 (1999), pp. 1398-1405
[54.]
R.J. Farrell, S.A. Shah, P.J. Lodhavia, M. Alsahli, K.R. Falchuk, P. Michetti, et al.
Clinical experience with infliximab therapy in 100 patients with Crohn’s disease.
Am J Gastroenterol, 95 (2000), pp. 3490-3497
[55.]
R.D. Cohen, J.F. Tsang, S.B. Hanauer.
Infliximab in Crohn’s disease: first anniversary clinical experience.
Am J Gastroenterol, 95 (2000), pp. 3469-3477
[56.]
P. Rutgeerts, G.R. D’Haens, S. Targan, E.A. Vasiliauskas, S.B. Hanauer, D.H. Present, et al.
Eficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease.
Gastroenterology, 117 (1999), pp. 761-769
[57.]
R.J. Farrell, M. Alsahli, K.R. Falchuk, M.A. Peppercorn, P. Michetti.
Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy [abstract].
Gastroenterology, 120 (2001), pp. A69
[58.]
W.J. Sandborn, E.C. Van Os, B.J. Zins, W.J. Tremaine, D.C. Mays, J.J. Lipsky.
An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease.
Gastroenterology, 109 (1995), pp. 1808-1817
[59.]
W.J. Sandborn, W.J. Tremaine, D.C. Wolf, S.R. Targan, C.A. Sninsky, L.R. Sutherland, et al.
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease.
Gastroenterology, 117 (1999), pp. 527-535
[60.]
D.H. Casson, S.E. Davies, M.A. Thomson, A. Lewis, J.A. Walker-Smith, S.H. Murch.
Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease.
Aliment Pharmacol Ther, 13 (1999), pp. 891-895
[61.]
U. Mahadevan, W.J. Tremaine, T. Johnson, M.G. Pike, D.C. Mays, J.J. Lipsky, et al.
Intravenous azathioprine in severe ulcerative colitis: a pilot study.
Am J Gastroenterol, 95 (2000), pp. 3463-3468
[62.]
D.H. Present, S.J. Meltzer, M.P. Krumholz, A. Wolke, B.I. Korelitz.
6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity.
Ann Intern Med, 111 (1989), pp. 641-649
[63.]
C.J. Haber, S.J. Meltzer, D.H. Present, B.I. Korelitz.
Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease.
Gastroenterology, 91 (1986), pp. 982-986
[64.]
W.R. Connell, M.A. Kamm, J.K. Ritchie, J.E. Lennard-Jones.
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease-27 years of experience.
Gut, 34 (1993), pp. 1081-1085
[65.]
B.I. Korelitz, S.R. Fuller, J.I. Warman, M.D. Goldberg.
Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease.
Am J Gastroenterol, 94 (1999), pp. 424-426
[66.]
M.C. Dubinsky, S. Lamothe, H.Y. Yang, S.R. Targan, D. Sinnett, Y. Théorêt, et al.
Pharmacogenomics and metabolite measurements for 6-mercaptopurine therapy in inflammatory bowel disease.
Gastroenterology, 118 (2000), pp. 705-713
[67.]
W.R. Connell, M.A. Kamm, M. Dickson, A.M. Blakwill, J.K. Ritchie, J.E. Lennard-Jones.
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Lancet, 343 (1994), pp. 1249-1252
[68.]
B.I. Korelitz, F.J. Mirsky, M.R. Fleisher, J.I. Warman, N. Wisch, G.M. Gleim.
Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Am J Gastroenterol, 94 (1999), pp. 3248-3253
[69.]
E.M. Alstead, J.K. Ritchie, J.E. Lennard-Jones, M.J.G. Farthing, M.L. Clark.
Safety of azathioprine in pregnancy in inflammatory bowel disease.
Gastroenterology, 99 (1990), pp. 443-446
[70.]
A. Francella, A. Dayan, P. Rubin, M. Chapman, D.H. Present.
6-Mercaptopurine is safe therapy for child bearing patients with inflammatory bowel disease: a case controlled study [abstract].
Gastroenterology, 110 (1996), pp. A909
[71.]
R.O. Rajapakse, B.I. Korelitz, J. Zlatanic, P.J. Baiocco, G.M. Gleim.
Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease.
Am J Gastroenterol, 95 (2000), pp. 684-688
[72.]
W.R. Connell.
Safety of drug therapy for inflammatory bowel disease in pregnant and nursing women.
Inflammat Bowel Dis, 2 (1996), pp. 33-47
[73.]
S.V. Kane.
What’s good for the goose should be good for the gander: 6-MP use in fathers with inflammatory bowel disease.
Am J Gastroenterol, 95 (2000), pp. 581-582
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
